Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2016 / Article

Corrigendum | Open Access

Volume 2016 |Article ID 9567408 | https://doi.org/10.1155/2016/9567408

K. Watanabe, A. Shimada, K. Miyaki, A. Hirakata, K. Matsuoka, K. Omae, I. Takei, "Corrigendum to “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial”", Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 9567408, 1 page, 2016. https://doi.org/10.1155/2016/9567408

Corrigendum to “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial”

Received26 Jan 2016
Accepted19 Jun 2016
Published19 Jul 2016

In the article titled “Long-Term Effects of Goshajinkigan in Prevention of Diabetic Complications: A Randomized Open-Labeled Clinical Trial” [1], we have noticed inadvertent errors. We would like to correct the errors here. These errors do not change the scientific conclusions of the paper.

(1) The abbreviation “DN” in the third paragraph of Section 2.4 “Primary and Secondary Outcomes” did not mean “diabetic nephropathy” and should be corrected as “diabetic neuropathy.”

(2) Section 3.1 “Participants Registration, Allocation, Follow-Up, and Analysis” should be corrected as follows: A total of 332 patients were registered for this clinical trial (Figure 1), among which 183 patients were excluded because of being out of criteria. Main reason of the exclusion was the retinopathy. Even though, in the regular ophthalmological check, these patients matched the inclusion criteria, fundus photography revealed that these patients did not match the inclusion criteria. Another reason was out of goshajinkigan pattern. This was relatively difficult for the physician who contributed to this study. As a result, 149 patients were allocated to goshajinkigan (GJG) group () and to control group ().

(3) Section 3.4 “Secondary Outcomes” should be corrected as follows: The hazard ratio was calculated as 0.436 (95% CI: 0.198–0.962), and the value was 0.030 determined by the log-rank test (Figure 5).

References

  1. K. Watanabe, A. Shimada, K. Miyaki et al., “Long-term effects of goshajinkigan in prevention of diabetic complications: a randomized open-labeled clinical trial,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 128726, 8 pages, 2014. View at: Publisher Site | Google Scholar

Copyright © 2016 K. Watanabe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views653
Downloads328
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.